Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

NovoCure Limited NVCR

Healthcare — Medical Devices

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
2.98
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — 2 7 — — 8 — — —
Insider Ownership
9.78%

Capital & Financial Ratios

Market Cap
1,940.00
Revenue
699.19
Net Income
(148.56)
Free Cash Flow
(25.43)
Net Debt
(254.58)
Current Ratio
2.89
Debt/Equity
0.58
P/E ratio
0.00
P/S ratio
2.77
P/B ratio
5.73
Past 5Y EPS Growth
(83.87%)
This Y EPS Growth
(2.52%)
Next Y EPS Growth
34.73%
Next 5Y EPS Growth
32.69%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 912.36 962.20 457.52 450.48
Receivables 83.90 109.29 148.10 145.82
Inventory 38.15 35.09 41.11 42.22
Other — — — —
1,034.41 1,106.58 646.73 638.52
2023 2024 2025 Q'26
Payables 94.39 105.09 122.23 130.73
ST’ Debt — — — —
Other — — — —
179.12 756.39 223.23 220.71
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 174.06 183.58 — —
—
’25 154.99 158.81 167.20 174.35
655.35
’24 138.50 150.36 155.10 161.27
605.22
’23 122.18 126.05 127.32 133.78
509.34
’22 137.55 140.87 131.00 128.43
537.84
’21 134.70 133.52 133.61 133.21
535.03
’20 101.83 115.93 132.66 143.95
494.37
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (13.52) 8.13 — —
—
’25 (35.66) (15.94) 20.57 (18.00)
(49.03)
’24 (31.57) (1.72) 10.38 (3.45)
(26.37)
’23 (16.73) (22.74) (19.31) (14.56)
(73.34)
’22 (3.69) 15.76 22.42 (3.71)
30.79
’21 17.78 26.17 24.40 14.40
82.76
’20 1.96 12.74 30.97 53.48
99.15
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (18.67) 1.22 — —
—
’25 (46.28) (21.42) 14.92 (22.90)
(75.68)
’24 (43.36) (13.17) (0.31) (12.39)
(69.22)
’23 (22.81) (29.67) (26.57) (21.38)
(100.43)
’22 (8.78) 11.63 16.72 (10.14)
9.43
’21 13.80 23.55 21.10 0.13
58.59
’20 (1.15) 9.43 28.19 47.72
84.18
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.62) (0.13) — —
—
’25 (0.31) (0.36) (0.33) (0.22)
(1.22)
’24 (0.36) (0.31) (0.28) (0.61)
(1.56)
’23 (0.50) (0.54) (0.46) (0.45)
(1.95)
’22 (0.04) (0.23) (0.25) (0.36)
(0.88)
’21 (0.04) (0.14) (0.13) (0.25)
(0.56)
’20 0.04 0.02 0.09 0.04
0.18

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.9
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 56.39 10.87 11.70 10.70 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 90.98 120.03 34.13 31.17 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,320 1,453 1,488 1,605 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.41 0.35 0.41 0.41 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 537.84 509.34 605.22 655.35 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 78.64% 74.81% 77.33% 74.54% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (81.85) (191.74) (131.16) (136.25) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15.22%) (37.64%) (21.67%) (20.79%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (92.53) (207.04) (168.63) (136.23) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.09 (12.11) (14.41) (8.61) — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.14 4.79 5.61 5.88 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ (0.88) (1.95) (1.56) (1.22) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.29 (0.69) (0.24) (0.44) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.20) (0.25) (0.40) (0.24) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.09 (0.94) (0.64) (0.68) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.22 3.41 3.34 3.05 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 104.66 106.39 107.83 111.47 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.22 3.01 5.31 2.20 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16.12 4.23 8.92 4.23 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.48 2.35 3.92 1.81 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 711.79 (11.89) (34.30) (15.66) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 30.79 (73.34) (26.37) (49.03) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (21.36) (27.09) (42.85) (26.65) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.43 (100.43) (69.22) (75.68) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 952.75 855.29 350.18 423.50 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 571.51 568.82 117.27 236.69 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (398.42) (343.54) (844.93) (220.82) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 441.17 362.50 360.18 340.47 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (7.94%) (17.71%) (14.13%) (13.32%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (130.89%) (767.68%) 0.00% (80.34%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (21.73%) (51.52%) (46.67%) (38.89%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

NovoCure (NVCR), pioneer in tumor treating fields therapy for tough cancers like glioblastoma, delivered explosive revenue growth—from $83 million in 2016 to $605 million in 2024, with robust 77% gross margins and forecasts for steady 8-10% annual increases through 2027. Yet, despite this top-line resilience and expansions into lung and other cancers via devices like Optune, the stock plunged from a $232 peak in 2021 to ~$11 today, hammered by reimbursement woes, trial delays, and ballooning losses (EPS -$1.56 in 2024). This disconnect screams potential undervaluation, especially with EV/Sales at a dirt-cheap 3.9x.

A fortress balance sheet bolsters the case: net cash position of -$865 million after slashing debt 83%, ample working capital, and insiders doubling down—CEO and CFO buying heavily at lows, outpacing routine sells. Cash burn persists with negative FCF, but narrowing losses are projected, hinting at an inflection if trials like ovarian/lung cancer readouts deliver.

Analysts see 23-330% upside, betting on revenue acceleration and pipeline wins to rerate the stock. Risks loom—prolonged red ink, trial flops, or reimbursement snags could deepen the pain—but with fundamentals grinding higher and leadership convicted, NVCR looks like a high-conviction rebound bet for patient investors.

Read full commentary →

NovoCure Limited (NVCR) Latest News

News by impact score

Fine-tune

18 Sep

4 www.marketbeat.com, 10:02 AM
NovoCure targets glioblastoma growth, plans new cancer therapy launches, and aims for EBITDA break-even. Glioblastoma expansion, multiple launches, and EBITDA milestone point to major strategic and financial shifts for NVCR.

7 Sep

3 , 11:12 AM
NovoCure Limited disclosed a cybersecurity incident exposing patient data. Patient data exposure creates regulatory and reputational risks with possible short-term operational effects.

14 Aug

3 www.trefis.com, 5:54 PM
Speculation centers on NovoCure Limited as a possible acquirer of Inspire Medical Systems, highlighting potential consolidation moves among medtech firms in sleep and oncology device markets. Acquisition speculation may influence investor views on NovoCure's growth strategy but lacks confirmed actions or immediate financial effects.

27 Jul

3 , 9:15 AM
NovoCure Limited shows shifting international revenue patterns across regions with unexpected results in select markets that point to growth opportunities and risks ahead. Revenue trend analysis can moderately affect financial results and market views without major strategic shifts.

25 Jul

4 , 3:11 AM
NovoCure (NVCR) raised 2026 guidance after posting a record quarter, while fair value debate continues among investors. Guidance lift after record results signals major financial momentum likely to shift investor sentiment and company trajectory.

24 Jul

3 transcript app.moby.co, 8:30 AM
NovoCure Limited held its Q2 2026 earnings call covering quarterly financial results, operational updates, and forward guidance. Quarterly earnings call provides financial results and guidance that can influence near-term stock sentiment but rarely shifts long-term company trajectory alone.

23 Jul

4 , 8:43 PM
Novocure (NVCR) stock reaches new high on optimistic outlook and FDA approval hopes. Optimistic outlook combined with FDA approval prospects signals major shifts in company trajectory and market sentiment.

4 stocktwits.com, 4:09 PM
NVCR stock surged 28% in a single day, marking its strongest performance in over 1.5 years amid a rally driven by unspecified factors. NVCR's 28% single-day gain signals major positive developments likely to shift investor sentiment and company trajectory.

4 transcript , 3:01 PM
NovoCure Ltd posted record revenue in Q2 2026 with ongoing strategic growth initiatives. Record revenue from Q2 2026 directly boosts financial results and market positioning.

4 investorshub.advfn.com, 11:33 AM
NovoCure reports record second-quarter revenue from Optune expansion and raises its 2026 outlook. Record revenue and higher 2026 guidance point to major positive effects on NVCR growth and sentiment.

4 , 7:00 AM
NovoCure Limited reported financial results for the second quarter of 2026. Quarterly financial results directly influence stock valuation and investor outlook for NVCR.

3 transcript www.marketbeat.com, 9:06 AM
NovoCure Limited presented Q2 financial results and operational updates in its earnings call, covering revenue performance, adoption of Tumor Treating Fields therapy, and guidance on future growth initiatives. Quarterly earnings data and updates can moderately shift investor views on financial trajectory without major strategic overhauls.

16 Jul

3 , 10:00 AM
NovoCure (NVCR) is positioned to report negative earnings in its next quarterly release, with trends pointing to continued financial pressure ahead of the announcement. Anticipation of negative earnings can exert short-term downward pressure on NVCR shares and investor sentiment without altering long-term fundamentals.

1 Jul

4 , 1:00 PM
NovoCure Limited received European approval for its Option Pax cancer treatment device. European approval expands NovoCure market access and revenue potential for its core device.

30 Jun

4 , 7:00 AM
NovoCure’s Optune Pax® received CE Mark approval for treating locally advanced pancreatic cancer. CE Mark expands Optune Pax access to European pancreatic cancer market and lifts revenue potential.

20 Jun

4 , 4:07 PM
NovoCure (NVCR) stock appears 45.2% below fair value following TRIDENT trial miss. TRIDENT trial miss directly undermines NovoCure pipeline progress and share valuation trajectory.

18 Jun

4 www.clinicaltrialsarena.com, 12:04 PM
NovoCure’s Optune Gio failed to demonstrate benefit in earlier-stage use, blocking potential label expansion. Trial miss directly reduces addressable market and growth outlook for Optune Gio.

4 www.medicaldevice-network.com, 12:04 PM
Novocure’s Optune Gio fails to show benefit at earlier stage. Failure to demonstrate benefit at earlier stage blocks label expansion and caps NovoCure revenue growth.

4 , 9:29 AM
NovoCure shares tumbled after its Tumor Treating Fields device failed a phase 3 trial for brain cancer, removing a key potential revenue driver. Core product failure in brain cancer directly damages primary growth path and market valuation.

4 investorshub.advfn.com, 8:53 AM
Novocure shares declined after its Phase 3 glioblastoma study missed the primary survival endpoint. Phase 3 glioblastoma trial failure signals major setback for NVCR pipeline and market position.

4 , 7:00 AM
NovoCure announced topline data from Phase 3 TRIDENT trial on earlier Tumor Treating Fields therapy use in newly diagnosed glioblastoma. Positive Phase 3 trial data may expand adoption of core Tumor Treating Fields therapy and alter growth trajectory.

2 May

4 Simply Wall St., 9:13 AM
NovoCure Limited (NVCR) reported first-quarter earnings, sparking questions on whether analysts have revised their stock outlook. Q1 earnings disclosures frequently trigger analyst revisions that significantly sway investor sentiment and market trajectory.

30 Apr

4 app.moby.co, 8:45 PM
NovoCure Limited released Q1 2026 earnings call summary detailing quarterly financial results, revenue updates, operational progress, and forward guidance. Q1 2026 earnings call summary covers critical financial performance and strategic updates that can significantly sway investor sentiment and stock trajectory.

4 transcript www.fool.com, 5:02 PM
NovoCure (NVCR) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses key financial metrics, revenue growth, and strategic outlook significantly shaping NVCR's trajectory and investor sentiment.

4 www.marketbeat.com, 9:20 AM
NovoCure reported Q1 2024 revenue of $138.1 million, up 8% year-over-year and beating estimates, fueled by 15% glioblastoma growth; raised full-year revenue guidance to $550-580 million; highlighted new clinical data for pancreatic and ovarian cancers; shares fell over 20% post-call on higher expenses. Earnings beat and raised guidance signal strong operational momentum and pipeline progress, likely boosting long-term investor confidence despite short-term stock reaction.

4 Business Wire, 7:00 AM
NovoCure Limited reported first quarter 2026 financial results. Quarterly earnings reports typically drive significant stock price movements and shape investor expectations for future performance.

3 Zacks, 8:30 AM
NovoCure Limited (NVCR) reported a wider-than-expected Q1 net loss of $0.64 per share but beat revenue estimates with $138.1 million, up 4% year-over-year, driven by increased Tumor Treating Fields therapy adoption amid ongoing investments in pancreatic and lung cancer trials. Q1 revenue beat signals top-line strength and therapy adoption growth, offsetting the loss and providing moderate positive influence on financial trajectory and investor sentiment.

2 Apr

4 Simply Wall St., 2:10 AM
NovoCure (NVCR) shares dropped 6.6% despite strong Phase 2 PANOVA-4 trial data showing improved survival in metastatic pancreatic cancer patients, prompting debate on whether the bullish investment thesis has shifted. Strong Phase 2 data in metastatic pancreatic cancer signals major pipeline expansion for NovoCure, potentially transforming its oncology portfolio despite short-term stock decline.

26 Mar

4 Business Wire, 7:00 AM
NovoCure announced positive topline results from the Phase 2 PANOVA-4 clinical trial of Tumor Treating Fields (TTFields) therapy in patients with metastatic pancreatic cancer, showing significant improvement in progression-free survival. Positive Phase 2 results validate TTFields efficacy in metastatic pancreatic cancer, a high-unmet-need indication, potentially expanding NVCR's market and driving significant investor interest.

9 Mar

4 Zacks, 11:53 AM
NovoCure's Optune Lua receives reimbursement approval in Japan for NSCLC treatment, enabling broader patient access and potential revenue growth in a key market. Japan reimbursement for Optune Lua in NSCLC unlocks significant market access and revenue potential in a major healthcare market.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us